Cargando…

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

Mice with thyroid-specific expression of oncogenic BRAF (Tg-Braf) develop papillary thyroid cancers (PTC) that are locally invasive and have well-defined foci of poorly differentiated carcinoma (PDTC). To investigate the PTC-PDTC progression, we performed a microarray analysis using RNA from paired...

Descripción completa

Detalles Bibliográficos
Autores principales:	Knauf, Jeffrey A, Sartor, Maureen A, Medvedovic, Mario, Lundsmith, Emma, Ryder, Mabel, Salzano, Marcella, Nikiforov, Yuri E, Giordano, Thomas J, Ghossein, Ronald A, Fagin, James A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136543/ https://www.ncbi.nlm.nih.gov/pubmed/21383698 http://dx.doi.org/10.1038/onc.2011.44

Ejemplares similares

Genetic and Pharmacological Targeting of CSF-1/CSF-1R Inhibits Tumor-Associated Macrophages and Impairs BRAF-Induced Thyroid Cancer Progression
por: Ryder, Mabel, et al.
Publicado: (2013)

Telomerase reactivation induces progression of mouse Braf(V600E)-driven thyroid cancers without telomere lengthening
por: Landa, Iñigo, et al.
Publicado: (2023)

BRAF(V600E) Induction in Thyrocytes Triggers Important Changes in the miRNAs Content and the Populations of Extracellular Vesicles Released in Thyroid Tumor Microenvironment
por: Delcorte, Ophélie, et al.
Publicado: (2022)

Mouse Models as a Tool for Understanding Progression in Braf(V600E)-Driven Thyroid Cancers
por: Landa, Iñigo, et al.
Publicado: (2019)

Co-inhibition of SMAD and MAPK signaling enhances (124)I uptake in BRAF-mutant thyroid cancers
por: Luckett, Kathleen A, et al.
Publicado: (2021)

Concomitant BRAF Mutation in Hairy Cell Leukemia and Papillary Thyroid Cancer: Case Report
por: Mohamed, Shehab F., et al.
Publicado: (2019)

Loss of IκB kinase β promotes myofibroblast transformation and senescence through activation of the ROS-TGFβ autocrine loop
por: Chen, Liang, et al.
Publicado: (2016)

Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors
por: Garcia-Rendueles, Maria E. R., et al.
Publicado: (2022)

Update to the College of American Pathologists Reporting on Thyroid Carcinomas
por: Ghossein, Ronald
Publicado: (2009)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

Targeting BRAF in thyroid cancer
por: Espinosa, A V, et al.
Publicado: (2007)

Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto’s thyroiditis: a systematic review with meta-analysis
por: Janicki, Lukasz, et al.
Publicado: (2023)

Concomitant KIT/BRAF and PDGFRA/BRAF mutations are rare events in gastrointestinal stromal tumors
por: Rossi, Sabrina, et al.
Publicado: (2016)

BRAF(V600E) Expression in Thyrocytes Causes Recruitment of Immunosuppressive STABILIN-1 Macrophages
por: Spourquet, Catherine, et al.
Publicado: (2022)

Clinical detection and categorization of uncommon and concomitant mutations involving BRAF
por: Zheng, Gang, et al.
Publicado: (2015)

Critical Prognostic Parameters in the Anatomic Pathology Reporting of Differentiated Follicular Cell-Derived Thyroid Carcinoma
por: Xu, Bin, et al.
Publicado: (2019)

BRAF in Papillary Thyroid Carcinoma
por: Lanzilotta, Salvatore Giovanni, et al.
Publicado: (2007)

BRAF and TERT mutations in papillary thyroid cancer patients of Latino ancestry
por: Estrada-Flórez, Ana P, et al.
Publicado: (2019)

Transformation by Hras(G12V) is Consistently Associated with Mutant Allele Copy Gains and is Reversed by Farnesyl Transferase Inhibition
por: Chen, Xu, et al.
Publicado: (2013)

Concomitant BCORL1 and BRAF Mutations in Vemurafenib-Resistant Melanoma Cells()
por: Mologni, Luca, et al.
Publicado: (2018)

MODL-01. SAFETY IN CONCOMITANT USE OF MEK AND BRAF INHIBITORS WITH BEVACIZUMAB
por: Winzent, Shelby, et al.
Publicado: (2020)

Intensity-based hierarchical Bayes method improves testing for differentially expressed genes in microarray experiments
por: Sartor, Maureen A, et al.
Publicado: (2006)

Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein
por: Zhang, Yanxiao, et al.
Publicado: (2015)

Putative BRAF activating fusion in a medullary thyroid cancer
por: Kasaian, Katayoon, et al.
Publicado: (2016)

Characteristics of and Treatment Strategies for Advanced EGFR-Mutant NSCLC With Concomitant BRAF Variations
por: Wei, Xue-Wu, et al.
Publicado: (2022)

Five-Year Survival Is Similar in Thyroid Cancer Patients with Distant Metastases Prepared for Radioactive Iodine Therapy with either Thyroid Hormone Withdrawal or Recombinant Human TSH
por: Tala, H., et al.
Publicado: (2011)

BRAF Testing in Multifocal Papillary Thyroid Carcinoma
por: Kimbrell, Hillary Z., et al.
Publicado: (2015)

BRAF inhibition with concomitant tumor treating fields for a multiply progressive pleomorphic xanthoastrocytoma
por: Lukas, Rimas V, et al.
Publicado: (2018)

Transcriptome Analyses in Normal Prostate Epithelial Cells Exposed to Low-Dose Cadmium: Oncogenic and Immunomodulations Involving the Action of Tumor Necrosis Factor
por: Bakshi, Shlomo, et al.
Publicado: (2008)

Dual EGFR and BRAF blockade overcomes resistance to vemurafenib in BRAF mutated thyroid carcinoma cells
por: Notarangelo, Tiziana, et al.
Publicado: (2017)

International Medullary Thyroid Carcinoma Grading System: A Validated Grading System for Medullary Thyroid Carcinoma
por: Xu, Bin, et al.
Publicado: (2022)

Rare Though Not Mutually Exclusive: A Report of Three Cases of Concomitant KRAS and BRAF Mutation and a Review of the Literature
por: Sahin, Ibrahim Halil, et al.
Publicado: (2013)

Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer
por: Zaballos, Miguel A., et al.
Publicado: (2022)

The Utility of BRAF Testing in the Management of Papillary Thyroid Cancer
por: Melck, Adrienne L., et al.
Publicado: (2010)

Epigenetic modification and BRAF gene mutation in thyroid carcinoma
por: Huang, Guo, et al.
Publicado: (2021)

Comparability of the small RNA secretome across human biofluids concomitantly collected from healthy adults
por: Langevin, Scott M., et al.
Publicado: (2020)

Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis
por: Kim, Woon Won, et al.
Publicado: (2018)

Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer
por: Zhang, Yanxiao, et al.
Publicado: (2016)

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients
por: Hecht, Markus, et al.
Publicado: (2018)

KRAS and BRAF Concomitant Mutations in a Patient with Metastatic Colon Adenocarcinoma: An Interesting Case Report
por: Cafiero, Concetta, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4igv3g59a6v4jfkhiej628idbg